Premium
The Pharmacokinetics of Thiabendazole and its Metabolites in an Anephric Patient Undergoing Hemodialysis and Hemoperfusion
Author(s) -
BAUER LARRY A.,
RAISYS VIDMANTAS A.,
WATTS MARK T.,
BALLINGER JOHN
Publication year - 1982
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1982.tb02674.x
Subject(s) - hemoperfusion , pharmacokinetics , hemodialysis , metabolite , volume of distribution , dosing , pharmacology , medicine , glucuronide , chemistry
The pharmacokinetics of thiabendazole and its metabolites were determined after the first dose and during hemodialysis and hemoperfusion in an anephric female patient treated for a strongyloides infection. The half‐life, volume of distribution, and clearance for thiabendazole were 1.17 hour, 2.76 liters/kg, and 27.2 ml/min · kg, respectively. While thiabendazole and the 5‐OH metabolite did not accumulate during multiple dosing, the glucuronide and sulfate esters accumulated extensively despite hemodialysis and hemoperfusion. Hemodialysis clearances for all compounds were poor. Hemoperfusion removal was much better but declined rapidly after the first hour. If rapid removal of thiabendazole and its metabolites is required, the hemoperfusion column should be changed hourly.